Zagociguat
Zagociguat ( , ; developmental code names CY-6463 and IW-6463) is a brain-penetrant soluble guanylate cyclase (sGC) stimulator which is under development for the treatment of Alzheimer's disease, MELAS syndrome, mitochondrial disorders…
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Zagociguat ( , ; developmental code names CY-6463 and IW-6463) is a brain-penetrant soluble guanylate cyclase (sGC) stimulator which is under development for the treatment of Alzheimer's disease, MELAS syndrome, mitochondrial disorders, dementia, and schizophrenia. It is taken orally. The drug shows pro-cognitive-like and neuroprotective effects in preclinical research.
Zagociguat was originated by Ironwood Pharmaceuticals and is under development by Cyclerion Therapeutics and/or Tisento Therapeutics. As of January 2026, it is in phase 2 clinical trials for Alzheimer's disease, MELAS syndrome, and mitochondrial disorders, whereas no recent development has been reported for dementia or schizophrenia.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372054473 under CC BY-SA 4.0; modifications have been made.